Tissue Plasminogen Activator for preclinical stroke research: Neither “rat” nor “human” dose mimics clinical recanalization in a carotid occlusion model

Amelia J. Tomkins1,2, Rebecca J. Hood1,2, Christopher R. Levi2,3,4 & Neil J. Spratt1,2,3

Tissue plasminogen activator (tPA) is the only approved thrombolytic therapy for acute ischemic stroke, yet many patients do not recanalize. Enhancing thrombolytic efficacy of tPA is a major focus of stroke research. Traditionally, a “rat dose” of 10 mg/kg has been used in rodent models. Recent studies suggested that the clinical “human” dose (0.9 mg/kg) may better mimic clinical recanalization. These studies only compared the rat and clinical doses, and so we aimed to test recanalization efficacy of multiple tPA doses ranging from 0.9 to 10 mg/kg in a model of endothelial injury and vessel stenosis. The common carotid artery of rats was crushed and stenosed to allow in situ occlusive thrombus formation (Folt’s model of ‘physiological’ thrombus). Intravenous tPA was administered 60 minutes post-occlusion (n = 6-7/group). Sustained recanalization rates were 0%, 17%, 67% and 71%, for 0.9, 1.8, 4.5, and 10 mg/kg, respectively. Median time to sustained recanalization onset decreased with increasing dosage. We conclude that 10 mg/kg of tPA is too effective, whereas 0.9 mg/kg is ineffective for lysis of occlusive thrombi formed in situ. Neither dose mimics clinical tPA responses. A dose of 2x the clinical dose is a more appropriate mimic of clinical tPA recanalization in this model.

Tissue plasminogen activator (tPA) is the only approved thrombolytic therapy for acute ischemic stroke. Early recanalization of occluded vessels is associated with improved clinical outcome, yet less than 50% of all stroke patients treated intravenously with tPA will successfully recanalize1. In the setting of carotid artery occlusion, tPA is even less effective, with recanalization rates of 10–30%2,3. There is a great need for improved therapies for stroke and one approach has been to enhance thrombolysis with adjuvant therapies such as sonothrombolysis4. For any new or adjuvant thrombolytic therapy, rigorous preclinical testing should occur and aim to mimic the clinical conditions of ischemic stroke and tPA efficacy. There has been controversy regarding what a “human equivalent” dose of tPA is for preclinical research—particularly in rodents, in which most such studies are performed.

Traditionally, a dose of 10 mg/kg tPA has been used for rodents. This “rat dose” was based on an in vitro study from the early 1980’s that demonstrated that the fibrinolytic system of rats is 10-fold less sensitive than humans5. Two recent comparisons of rat and clinical doses in rats6 and mice7 both...
indicated that the clinical dose was a better mimic of the clinical situation. Additional doses were not compared in these studies. The typical method for determining a “human equivalent” dose of any therapeutic utilizes a conversion based on body surface area of humans to the target species. For rats, this conversion requires multiplication of the human dose (0.9 mg/kg) by 6.2, indicating a “human equivalent” dose of 5.58 mg/kg tPA for rats. However, this conversion does not take into account additional factors that may affect the fibrinolytic process other than body size, and is not generally used when converting doses of tPA for stroke research.

Multiple methods of forming experimental thrombi exist for preclinical stroke models. Formation of thrombi in situ or ex vivo and the presence or absence of added pro-thrombotic factors, such as thrombin and/or CaCl₂, leads to variability of final thrombus composition. All of these factors play a key role in the overall thrombolytic susceptibility of the thrombus and therefore the variability of tPA efficacy between studies. Ideally, a preclinical model for testing stroke thrombolytics and thrombolytic enhancers should use thrombi that closely mimic human stroke thrombi and have similar recanalization rates.

For this study, we developed a method of physiological thrombus formation by endothelial injury and stenosis of the carotid artery in rats. To determine which tPA dose best reflects clinical recanalization rates in this model, we aimed to investigate sustained recanalization rates of varying doses of tPA ranging from the clinical dose to the traditional rat dose. Time to sustained recanalization was a secondary outcome.

Results
To test the thrombolytic efficacy of varied doses of tPA on a physiological thrombus we used a rat model of carotid occlusion with a mild underlying stenosis. Recanalization was monitored every 30 minutes post-tPA delivery to 4.5 hours post-occlusion. Sustained recanalization, defined as recanalization without reocclusion, was observed in 0% of 0.9 mg/kg treated rats (0/6), 17% of 1.8 mg/kg treated rats (1/6), 67% of 4.5 mg/kg treated rats (4/6), and 71% of 10 mg/kg treated rats (5/7) (Fisher’s exact test, p = 0.015, Fig. 1). Recanalization/reocclusion was observed in 2 animals, both in the 10 mg/kg dosage group. In pilot experiments we found that recanalization was easily confirmed (as in Fig. 3B). However accurate quantification of the degree of recanalization was not possible because coupling of the flow probe to the vessel with saline caused fluctuations in the baseline of the flow trace (data not shown). We did not see evidence of major changes in flow once vessels did recanalize. Therefore, in the interests of accuracy, we chose sustained recanalization as the marker of recanalization success based on dose, rather than attempting to quantify percentage recanalization.

Median times to recanalization (interquartile range) from start of tPA treatment were 210 (210–210) minutes for 0.9 mg/kg treated rats, 210 (210–210) minutes for 1.8 mg/kg treated rats, 65.5 (26–210) for 4.5 mg/kg treated rats, and 34 (27–210) minutes for 10 mg/kg treated rats (Log Rank Test, p = 0.017, Fig. 2). Earliest recanalization onset was 25 minutes (10 mg/kg), with no recanalization occurring beyond 87 minutes (27 minutes after tPA treatment end) in any group.

No animals were excluded. One animal died just prior to the final observation (10 mg/kg group). This animal had fluctuating body temperatures throughout surgery and high temperatures (> 39°C) leading up to its death, with no other explanation found. It was included in the primary analysis. Re-analysis
excluding this animal gave a recanalization rate of 83% (instead of 71%) for this group, but made no material difference to the primary findings.

**Discussion**
In this study, we found that the traditional rat dose of tPA (10 mg/kg) was highly effective for carotid artery recanalization (71% recanalization rate). This is far superior to what is achievable in clinical stroke, where recanalization rates are <50% for middle cerebral artery (MCA) occlusion\(^1\) and only 10–30% for occlusions of the carotid arteries\(^2,3\). The clinical dose of tPA (0.9 mg/kg) caused no recanalization in our model, which is also not reflective of the clinical situation. We found a 2x clinical dose (1.8 mg/kg) to better reflect clinical recanalization rates. We observed a possible ceiling effect at doses at and above 4.5 mg/kg (5x clinical dose). Our findings are in keeping with previous work showing that the rat fibrinolytic system is less sensitive than the human system. However, they suggest that the 10-fold difference in sensitivity found *in vitro*\(^5\) may overestimate the *in vivo* situation.
A “human equivalent” dose of tPA for preclinical research that results in recanalization rates reflective of the clinical setting has not previously been determined. We chose a range of doses spanning across those used in previous studies, with multiples of the clinical dose (i.e. 2x and 5x the clinical dose). Although the thrombolytic efficacy of tPA has been well established clinically, its efficacy is suboptimal and the growing field of research studying thrombolytic enhancers requires a preclinical dose of tPA that reflects the clinical response rates. Recent studies comparing clinical to rat dose reported the clinical dose to be a better clinical mimic, but these studies did not investigate additional doses14. The high recanalization rates we saw with the 10 mg/kg “rat” dose are similar to rates reported in other studies using this dose (67–100% in various stroke models11,13). These rates are not reflective of clinical recanalization and are particularly unsuited to studies of thrombolytic enhancer therapies, since there is little scope for additional benefit. Additionally, we found a possible ceiling effect of tPA dose at 4.5 mg/kg, with no significant increase in recanalization rates at the higher dose. Such an effect has also previously been reported for doses above 10 mg/kg14. For a “human equivalent” tPA dose, our study indicates that a 2x clinical dose (1.8 mg/kg) in this model with 17% recanalization rates best reflects clinical recanalization of carotid artery occlusion for which clinical rates are between 10–30%2,3. To achieve the higher end of this clinical range, a dose between 1.8 mg/kg and 4.5 mg/kg may be necessary. However, this highlights that the previously accepted doses are not ideal to mimic clinical rates. In other situations, such as MCA occlusion, clinical recanalization rates are higher than carotid occlusion1. Differing clot compositions and co-morbidities also affect recanalization efficacy with tPA15,16. It is likely that tPA doses required to mimic clinical recanalization rates will differ with regards to the model choice, incorporating clot type, co-morbidities, and species. We recommend that researchers aiming to find improved thrombolytic or recanalization therapies over tPA alone, need to determine the “human equivalent” dose for use in their chosen model that generates recanalization rates that correlate with the clinical conditions being tested.

We chose a model of naturally forming thrombi in order to create a physiological model as possible. This clot composition is the likely explanation for the complete lack of recanalization we saw with clinical dose tPA, in contrast to previous studies. Such studies have tended to use spontaneously formed thrombi, or other clot types with high sensitivities to tPA thrombolysis. Thrombus composition is well known to affect the efficacy of tPA lysis9,10. Our model, based on the Folt’s method, produces physiological thrombi that are platelet rich17. Platelet rich clots are histologically better mimics of clinical thrombi8 and are more resistant to thrombolysis than many other experimental thrombi19–21.

Recanalization was chosen as the primary outcome for this study because it is the major effect by which tPA causes clinical improvement1. In rat models of stroke, recanalization is not always reported due to difficulties in directly monitoring recanalization intracranially in the rat. The extracranial nature of our chosen model allowed direct real time monitoring of recanalization. We observed earlier onset time to recanalization with increasing doses of tPA. With early recanalization being predictive of good clinical outcome1, it is beneficial for enhancer therapies to not only increase the rates of recanalization, but to reduce the time to sustained recanalization onset. At higher doses, recanalization onset is already early (median time 34 minutes for 10 mg/kg), leaving little room for improvement if testing alternate therapies. Functional outcome was intentionally not included in this study because there is already convincing evidence that tPA produces good functional outcome in rodents1,22. We know from clinical studies that functional improvement is highly correlated with recanalization of the occluded artery. The purpose of this study was to determine whether the previously accepted “rat dose” causes recanalization rates too high to provide any scope for improvement when testing thrombolytic enhancers.

In conclusion, we have found that both rat and clinical doses of tPA are not reflective of clinical recanalization rates in a model of naturally forming thrombus. The rat dose was above that producing a “maximal” effect of recanalization. The no response observed with clinical tPA dose confirms that the rat fibrinolytic system is less sensitive to humans, but not to the 10-fold degree previously accepted. Neither dose appeared ideal for testing thrombolytic enhancers. For this model of carotid occlusion in rats, we propose a 2x clinical dose (1.8 mg/kg) to be best reflective of clinical recanalization rates.

Methods
Animals. This study was approved by the Animal Care and Ethics Committee of the University of Newcastle, Australia (Approval No. A-2010-128) and performed in compliance with requirements of the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes23. Male outbred Wistar rats (n = 25; 338–433 g; Animal Resources Centre, Perth, Australia) were anaesthetised with 5% Isoflurane, and maintained with 1.5–2% in 30/70% O2/N2 through a nose cone and rectal temperature was maintained at 37°C with a feedback controlled heat mat (Faculty of Health Workshop, University of Newcastle, Australia). Heart rate, respiration and oxygen saturation were monitored throughout surgery.

Carotid Artery Occlusion. To create a physiological thrombus to occlude the carotid artery, a modification of the Folt’s model17 was used with a mild underlying stenosis. The right carotid arteries were exposed and the internal carotid artery ligated to avoid risk of thromboembolism to the brain. Resultant strokes from carotid thromboembolism are highly variable, as in stroke patients, and could potentially confound experiments. A 20-MHz, 0.8 mm Doppler flow probe (Iowa Doppler Products, USA) was positioned over the external carotid artery to monitor blood flow. Baseline flow was recorded for 5 minutes prior to injury using LabChart 7 software (ADInstruments, Australia). The common carotid artery was
crushed three times (30 seconds with 30 second rest intervals, Fig. 3A) using haemostats guarded with tape to disrupt the endothelium, exposing pro-thrombotic factors. A double looped 5-0 silk suture was placed over the site of injury, and tightened to create stenosis following final crush. This stenosis reduced blood flow by 75% of pre-crush baseline flow. Flow was monitored for cyclic flow patterns until complete occlusion was achieved (Fig. 3A). An additional 30-second crush was made over the stenosis if: 1) continuous flow was maintained for 10 minutes after final crush, or 2) if cyclic flow patterns were observed for 30 minutes post-crush with no complete occlusion. No more than two additional crushes were performed in any animal. The tie was loosened 45 minutes after stable occlusion to establish a mild stenosis. Flow spontaneously returned pre-treatment in two animals. In one, the vessel was re-crushed, while the other recollapsed spontaneously within minutes. Sixty minute stable occlusion was again monitored before treatment.

**Treatment Groups.** At 60 minutes post-occlusion, animals were intravenously administered tPA (Alteplase, Boehringer Ingelheim, Australia) at the clinical dose (0.9 mg/kg, n = 6), 2x the clinical dose (1.8 mg/kg, n = 6), 5x the clinical dose (4.5 mg/kg, n = 6), or the rat dose (10 mg/kg, n = 7) as a 10% bolus over 1 minute, with the remainder infused over 1 hour.

The 0.9 mg/kg and 10 mg/kg groups were part of a separate study in which they had been randomised to either tPA or tPA + ultrasound treatment (tPA + ultrasound groups not presented here). The additional animals were randomized to either 1.8 or 4.5 mg/kg tPA for this study.

**Recanalization.** The primary outcome for this study was recanalization rates for each group. Recanalization was monitored every 30 minutes after tPA onset until 4.5 hours post-occlusion and presented as the total number of animals with sustained recanalization at experiment end per group. The end point of 4.5 hours was chosen based on the clinical time window for tPA treatment inclusion. Recanalization was reported as sustained when recanalization occurred and flow remained until the final observation time. Recanalization/reocclusion was reported when flow was observed at one time point and no flow observed at the next.

A secondary outcome of time to sustained recanalization was determined retrospectively from Labchart files by a blinded observer and was reported as the time that the flow trace returned to normal waveform post tPA treatment start, with the flow trace continuing as normal to experiment end (Fig. 3B).

**Statistics.** Sustained recanalization rates at endpoint were analysed for statistical significance using Fisher’s exact test. Time to sustained recanalization onset was assessed by survival analysis and log-rank test. Statistical significance was considered to be a p-value < 0.05.

**References**

1. Rha, J. H. & Saver, J. L. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38, 967–973 (2007).
2. Christou, I. et al. Intravascular tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion. J Neuroradiol 12, 119–123 (2002).
3. Pechlaner, R. et al. Recanalization of extracranial internal carotid artery occlusion after i.v. thrombolysis for acute ischemic stroke. PLoS One 8, e55318 (2013).
4. Tsivgoulis, G. et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 41, 280–287 (2010).
5. Korninger, C. & Collen, D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46, 561–565 (1981).
6. Haeflwyn, B., Risso, J. J. & Abraini, J. H. Human recombinant tissue-plasminogen activator (alteplase): why not use the human dose for stroke studies in rats? J Cereb Blood Flow Metab 30, 900–903 (2010).
7. El Amki, M. et al. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke. Exp Neurol 238, 138–144 (2012).
8. U.S. department of Health and Human Services, Food and drug administration. Centre for drug Evaluation and Research (CDER). Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Pharmacology and Toxicology (2005).
9. Niessen, F., Hilger, T., Hoehn, M. & Hossmann, K. A. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke 34, 2019–2024 (2003).
10. Overgaard, K. et al. Composition of emboli influences the efficacy of thrombolysis with rt-PA in a rat stroke model. Fibrinolysis 7, 141–148 (1993).
11. Busch, E., Kruger, K. & Hossmann, K. A. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res 778, 16–24 (1997).
12. Guluma, Z. K. & Laplachk, P. A. Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke. Brain Res 1354, 206–216 (2010).
13. Okubo, S. et al. Therapeutic time window of rt-PA on embolic stroke in rats. Int Congres Series 1252, 203–207 (2003).
14. Calandre, L., Grau, M. & Cabello, A. Lysis rates with rt-PB vary between different human emboli in a rat model of cerebral embolism. Fibrinolysis & Proteolysis 12, 107–111 (1998).
15. Ribo, M. et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 36, 1703–1709 (2005).
16. Tsivgoulis, G. et al. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke 38, 961–966 (2007).
17. Sturgeon, S. A., Jones, C., Angus, J. A. & Wright, C. E. Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals. J Pharmacol Toxicol Methods 53, 20–29 (2006).
18. Roessler, F. C. et al. Development of a new clot formation protocol for standardized in vitro investigations of sonothrombolysis. J Neurosci Methods 237, 26–32 (2014).
19. Collet, J. P. et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 21, 142–148 (2001).
20. Gold, H. K. et al. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. Circulation 83, IV26–40 (1991).
21. Tomkins, A. J. et al. Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke. Exp Transl Stroke Med 7, 2 (2015).
22. Sena, E. S. et al. Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. JCBFM 30, 1905–1913 (2010).
23. National Health and Medical Research Council (NHMRC). Australian code for the care and use of animals for scientific purposes, 8th edition. Canberra: National Health and Medical Research Council (2013).

Acknowledgements
The authors would like to acknowledge the technical assistance of Mrs Debbie Pepperall. Ms Amelia Tomkins was supported by a National Heart foundation/National Stroke Foundation Postgraduate Scholarship. Dr Neil Spratt was supported by an Australian National Health and Medical Research Council Career Development Fellowship (APP1035465).

Author Contributions
A.T., C.L. and N.S. were responsible for study design. Experimental procedures were performed by A.T. and R.H. Data analysis and manuscript preparation was by A.T. and N.S. All authors reviewed the final manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Tomkins, A. J. et al. Tissue Plasminogen Activator for preclinical stroke research: Neither “rat” nor “human” dose mimics clinical recanalization in a carotid occlusion model. Sci. Rep. 5, 16026; doi: 10.1038/srep16026 (2015).